US20040141983A1
(en)
|
1999-03-15 |
2004-07-22 |
Protein Design Labs, Inc. |
Compositions against cancer antigen LIV-1 and uses thereof
|
US7244827B2
(en)
|
2000-04-12 |
2007-07-17 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
|
US6946129B1
(en)
*
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
US7256257B2
(en)
*
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
PT1392359E
(pt)
|
2001-05-11 |
2010-01-27 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
EP3184539A3
(en)
|
2001-10-23 |
2017-09-13 |
PSMA Development Company L.L.C. |
Psma antibodies
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
AU2003243151A1
(en)
*
|
2002-08-16 |
2004-03-03 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
WO2004067564A2
(en)
*
|
2003-01-29 |
2004-08-12 |
Protein Design Labs, Inc. |
Compositions against cancer antigen liv-1 and uses thereof
|
US20080025989A1
(en)
*
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
ES2347959T3
(es)
|
2003-02-20 |
2010-11-26 |
Seattle Genetics, Inc. |
Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
|
CA2525929A1
(en)
|
2003-05-13 |
2004-11-25 |
Chiron Corporation |
Methods of modulating metastasis and skeletal related events resulting from metastases
|
KR101520209B1
(ko)
*
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
US20050175619A1
(en)
*
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
EP1718667B1
(en)
*
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
AU2005218642B2
(en)
*
|
2004-03-02 |
2011-04-28 |
Seagen Inc. |
Partially loaded antibodies and methods of their conjugation
|
WO2006012527A1
(en)
|
2004-07-23 |
2006-02-02 |
Endocyte, Inc. |
Bivalent linkers and conjugates thereof
|
US7641903B2
(en)
*
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US8337838B2
(en)
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
EP1799262A4
(en)
*
|
2004-10-15 |
2009-10-21 |
Seattle Genetics Inc |
ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
|
AU2005332660A1
(en)
*
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the N terminus
|
CA2589374C
(en)
|
2004-11-30 |
2016-05-03 |
Curagen Corporation |
Antibodies directed to gpnmb and uses thereof
|
US8165517B2
(en)
|
2005-01-19 |
2012-04-24 |
The Trustees Of The University Of Pennsylvania |
Methods for identifying inhibitors of vascular injury
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
DK1912677T3
(da)
*
|
2005-06-20 |
2014-01-13 |
Psma Dev Company L L C |
PSMA-antistof-lægemiddel-konjugater
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2722051B1
(en)
|
2005-07-07 |
2018-11-07 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
|
US8871720B2
(en)
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
CN101505800A
(zh)
*
|
2005-07-08 |
2009-08-12 |
艾伦药物公司 |
经由Mitsunobu反应制备VLA-4拮抗剂的聚乙二醇化共轭物
|
CA2616005C
(en)
*
|
2005-07-18 |
2015-09-22 |
Seattle Genetics, Inc. |
Beta-glucuronide-linker drug conjugates
|
NZ566395A
(en)
*
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
AR059900A1
(es)
|
2006-03-17 |
2008-05-07 |
Genentech Inc |
Anticuerpos anti-tat226 e inmunoconjugados
|
WO2007137260A2
(en)
*
|
2006-05-22 |
2007-11-29 |
Elan Pharmaceuticals, Inc. |
Preparation of polymer conjugates of vla-4 antagonists via a mitsunobu' s reaction
|
EP2446904B1
(en)
|
2006-05-30 |
2015-04-29 |
Genentech, Inc. |
Anti-CD22 antibodies, their immunoconjugates and uses thereof
|
WO2008025020A2
(en)
*
|
2006-08-25 |
2008-02-28 |
Seattle Genetics, Inc. |
Cd30 binding agents and uses thereof
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
WO2008070593A2
(en)
|
2006-12-01 |
2008-06-12 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
CA2672468A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
EP2126127B1
(en)
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
|
WO2008100805A2
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
AU2008227123B2
(en)
*
|
2007-03-15 |
2014-03-27 |
Ludwig Institute For Cancer Research Ltd. |
Treatment method using EGFR antibodies and src inhibitors and related formulations
|
BRPI0809435A2
(pt)
|
2007-03-27 |
2014-09-09 |
Sea Lane Biotechnologies Llc |
Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
|
GB0707034D0
(en)
*
|
2007-04-12 |
2007-05-23 |
St Andrews The |
Compounds
|
CA2683568A1
(en)
|
2007-05-08 |
2008-11-20 |
Genentech, Inc. |
Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
CA2690943A1
(en)
|
2007-06-25 |
2008-12-31 |
Endocyte, Inc. |
Conjugates containing hydrophilic spacer linkers
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
CN111499748A
(zh)
|
2007-07-16 |
2020-08-07 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
US20090035848A1
(en)
*
|
2007-08-03 |
2009-02-05 |
Robert Hickey |
Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
JP2010536790A
(ja)
|
2007-08-17 |
2010-12-02 |
パーデュー・リサーチ・ファウンデーション |
Psma結合性リガンド−リンカー結合体及び使用方法
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
CN101969970B
(zh)
*
|
2007-10-12 |
2014-10-15 |
西雅图基因公司 |
用抗体-药物偶联物联合治疗
|
PT2211904T
(pt)
|
2007-10-19 |
2016-11-02 |
Seattle Genetics Inc |
Agentes de ligação a cd19 e seus usos
|
EP3115469B1
(en)
|
2007-11-19 |
2020-04-29 |
Celera Corporation |
Lung cancer markers and uses thereof
|
EP2078492A1
(de)
*
|
2008-01-11 |
2009-07-15 |
Roche Diagnostics GmbH |
Bandkassette für ein medizinisches Handgerät und Blutzuckermesssystem
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
EP3269737B1
(en)
|
2008-01-31 |
2024-06-19 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
WO2009117531A1
(en)
*
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
CA2720699C
(en)
|
2008-04-11 |
2018-01-02 |
Seattle Genetics, Inc. |
Detection and treatment of pancreatic, ovarian and other cancers using antibodies that specifically bind to denatured cd70
|
CN104524590B
(zh)
|
2008-04-30 |
2019-06-21 |
伊缪诺金公司 |
交联剂和它们的用途
|
AU2009242453B2
(en)
|
2008-05-02 |
2014-12-04 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
US8835506B2
(en)
|
2008-06-05 |
2014-09-16 |
Stc.Unm |
Methods and related compositions for the treatment of cancer
|
PL2326350T3
(pl)
|
2008-09-08 |
2014-03-31 |
Psma Dev Company L L C |
Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
|
GB0819287D0
(en)
|
2008-10-22 |
2008-11-26 |
Univ Bradford |
Compounds
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
CA2749115C
(en)
|
2009-01-09 |
2022-06-21 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
WO2010096394A2
(en)
*
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
JP2012519711A
(ja)
*
|
2009-03-06 |
2012-08-30 |
アジェンシス,インコーポレイテッド |
24p4c12タンパク質に結合する抗体薬物結合体(adc)
|
EP2430047B1
(en)
|
2009-05-13 |
2018-03-28 |
i2 Pharmaceuticals, Inc. |
Neutralizing molecules to influenza viruses
|
SI2437790T1
(sl)
|
2009-06-03 |
2019-07-31 |
Immunogen, Inc. |
Konjugacijske metode
|
BRPI1015234A2
(pt)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
regiões fc projetadas para conjugação sítio específica.
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
JP2013505944A
(ja)
*
|
2009-09-24 |
2013-02-21 |
シアトル ジェネティックス, インコーポレイテッド |
Dr5リガンド薬物結合体
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
IN2012DN02780A
(el)
|
2009-10-06 |
2015-09-18 |
Immunogen Inc |
|
GEP20166504B
(en)
|
2009-10-23 |
2016-06-27 |
Millennium Pharm Inc |
Anti-gcc antibody molecules and related compositions and methods
|
PE20121584A1
(es)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
BR112012013975B8
(pt)
|
2009-12-09 |
2021-05-25 |
Inst Nat Sante Rech Med |
anticorpo monoclonal isolado, kit de diagnóstico, conjugado de anticorpo-fármaco, composição compreendendo o referido anticorpo, métodos in vitro para diminuir a atividade, para enfraquecer ou inibir o desenvolvimento de células e de detecção de expressão celular de b7h6, usos do anticorpo e do conjugado, e célula de produção de anticorpo
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
EA201201120A1
(ru)
|
2010-02-08 |
2013-03-29 |
Эдженсис, Инк. |
Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 161p2f10b
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
US9951324B2
(en)
|
2010-02-25 |
2018-04-24 |
Purdue Research Foundation |
PSMA binding ligand-linker conjugates and methods for using
|
PL2542576T3
(pl)
*
|
2010-03-02 |
2016-10-31 |
|
Sposoby badań przesiewowych przeciwciał
|
EP2552967A4
(en)
|
2010-04-02 |
2014-10-08 |
Amunix Operating Inc |
BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
|
US8697688B2
(en)
|
2010-04-15 |
2014-04-15 |
Seattle Genetics Inc. |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
SI3549963T1
(sl)
|
2010-04-15 |
2022-04-29 |
Kodiak Sciences Inc. |
Polimeri z visoko molekulsko maso, ki vsebujejo zwitterion
|
WO2011130613A1
(en)
|
2010-04-15 |
2011-10-20 |
Seattle Genetics, Inc. |
Targeted pyrrolobenzodiazapine conjugates
|
WO2011153346A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
EP2579897A1
(en)
|
2010-06-08 |
2013-04-17 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
PL2580243T3
(pl)
|
2010-06-09 |
2020-05-18 |
Genmab A/S |
Przeciwciała przeciwko ludzkiemu CD38
|
ES2528956T3
(es)
|
2010-06-10 |
2015-02-13 |
Seattle Genetics, Inc. |
Nuevos derivados de auristatina y su uso
|
NZ604718A
(en)
|
2010-06-15 |
2015-01-30 |
Genmab As |
Human antibody drug conjugates against tissue factor
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
EP2621508B1
(de)
|
2010-09-29 |
2015-08-26 |
Seattle Genetics, Inc. |
N-carboxyalkyl-auristatine und ihre verwendung
|
EP2621526B1
(en)
|
2010-09-29 |
2018-06-06 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 191p4d12 proteins
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
AU2011316917B2
(en)
|
2010-10-22 |
2016-02-25 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
PT3156420T
(pt)
|
2010-12-06 |
2019-05-27 |
Seattle Genetics Inc |
Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
|
TWI477513B
(zh)
|
2010-12-20 |
2015-03-21 |
建南德克公司 |
抗間皮素(mesothelin)抗體及免疫接合物
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
CA2829736C
(en)
|
2011-03-16 |
2020-07-21 |
Seattle Genetics, Inc. |
N-carboxyalkylauristatins and use thereof
|
JP6130307B2
(ja)
|
2011-03-17 |
2017-05-17 |
ザ ユニバーシティ オブ バーミンガム |
再指向性免疫療法
|
CA2831307A1
(en)
|
2011-03-30 |
2012-10-04 |
Arizona Board Of Regents, For And On Behalf Of, Arizona State Universi |
Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
|
WO2012143523A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
JP2014515753A
(ja)
|
2011-04-21 |
2014-07-03 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
新規な結合剤−薬物複合体(adc)およびそれらの使用
|
US8679767B2
(en)
|
2011-05-12 |
2014-03-25 |
Genentech, Inc. |
Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
|
EP2710024A4
(en)
|
2011-05-19 |
2015-04-29 |
Harvard College |
OSW-1 CONJUGATES AND ANALOGUES, AND USES THEREOF
|
KR102101806B1
(ko)
|
2011-05-19 |
2020-04-20 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-인간-her3 항체 및 이의 용도
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
MX371526B
(es)
*
|
2011-05-27 |
2020-01-31 |
Ambrx Inc |
Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
|
KR20200128601A
(ko)
*
|
2011-05-27 |
2020-11-13 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
|
LT3415531T
(lt)
|
2011-05-27 |
2023-09-25 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) – surišantys baltymai
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
RU2617402C2
(ru)
|
2011-06-10 |
2017-04-25 |
Мерсана Терапьютикс, Инк. |
Конъюгаты белок-полимер-лекарственное средство
|
CN103648532A
(zh)
|
2011-06-21 |
2014-03-19 |
伊缪诺金公司 |
具有肽连接子的新型美登木素生物碱衍生物及其偶联物
|
ES2677367T3
(es)
|
2011-06-22 |
2018-08-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anticuerpos anti-Axl y usos de los mismos
|
KR20140104944A
(ko)
|
2011-06-22 |
2014-08-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-axl 항체 및 그의 용도
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
AU2012311505B2
(en)
|
2011-09-20 |
2016-09-29 |
Medimmune Limited |
Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
|
EP3483611B1
(en)
|
2011-09-29 |
2023-01-04 |
Seagen Inc. |
Intact mass determination of protein conjugated agent compounds
|
DK2766392T3
(da)
|
2011-10-10 |
2019-10-07 |
Xencor Inc |
Fremgangsmåde til oprensning af antistoffer
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
AU2012322613B2
(en)
|
2011-10-14 |
2016-04-21 |
Medimmune Limited |
Pyrrolobenzodiazepines and targeted conjugates
|
US9388187B2
(en)
|
2011-10-14 |
2016-07-12 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
AU2012322934B2
(en)
|
2011-10-14 |
2016-09-08 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
CN108164551A
(zh)
|
2011-10-14 |
2018-06-15 |
西雅图基因公司 |
吡咯并苯并二氮杂卓和靶向结合物
|
PL2780039T3
(pl)
|
2011-11-17 |
2018-03-30 |
Pfizer Inc. |
Cytotoksyczne peptydy i ich koniugaty przeciwciało lek
|
JP2015500287A
(ja)
*
|
2011-12-05 |
2015-01-05 |
アイジェニカ・バイオセラピューティクス・インコーポレイテッドIgenica Biotherapeutics,Inc. |
抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法
|
WO2013096828A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
US9717803B2
(en)
|
2011-12-23 |
2017-08-01 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
KR102134490B1
(ko)
|
2012-01-12 |
2020-07-16 |
시냅틱스 인코포레이티드 |
단일층 용량성 이미징 센서들
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
CN108324943B
(zh)
|
2012-02-10 |
2024-03-08 |
思进股份有限公司 |
Cd30+癌症的检测和治疗
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
CA2867824A1
(en)
|
2012-05-01 |
2013-11-07 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
NZ724892A
(en)
|
2012-05-15 |
2018-04-27 |
Seattle Genetics Inc |
Self-stabilizing linker conjugates
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
JP6239598B2
(ja)
|
2012-05-15 |
2017-11-29 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
薬物複合体、複合体形成方法、およびその使用
|
US8822423B2
(en)
*
|
2012-05-17 |
2014-09-02 |
Janssen Biotech, Inc. |
Affinity peptides toward infliximab
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
KR101718200B1
(ko)
|
2012-05-21 |
2017-03-21 |
제넨테크, 인크. |
항-Ly6E 항체 및 면역접합체 및 사용 방법
|
US9522940B2
(en)
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
WO2013185114A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
EP4079316A1
(en)
|
2012-06-08 |
2022-10-26 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
US10132799B2
(en)
|
2012-07-13 |
2018-11-20 |
Innate Pharma |
Screening of conjugated antibodies
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
SI2692865T1
(sl)
|
2012-07-30 |
2015-03-31 |
Nbe-Therapeutics Llc Technology Parc Basel |
S transpozicijo posredovana identifikacija specifičnih vezavnih ali funkcionalnih proteinov
|
CN104717979A
(zh)
|
2012-08-02 |
2015-06-17 |
基因泰克公司 |
抗etbr抗体和免疫偶联物
|
JP2015529656A
(ja)
|
2012-08-02 |
2015-10-08 |
ジェネンテック, インコーポレイテッド |
抗etbr抗体および免疫複合体
|
CN105073132B
(zh)
|
2012-08-23 |
2020-01-10 |
艾更斯司股份有限公司 |
结合158p1d7蛋白的抗体药物偶联物(adc)
|
ES2728864T3
(es)
|
2012-08-31 |
2019-10-29 |
Sutro Biopharma Inc |
Aminoácidos modificados que comprenden un grupo azido
|
SI2906253T1
(sl)
|
2012-10-12 |
2018-11-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin-protitelo proti PSMA
|
ES2530968T3
(es)
|
2012-10-12 |
2015-03-09 |
Spirogen Sarl |
Pirrolobenzodiazepinas y conjugados de las mismas
|
ES2649990T3
(es)
|
2012-10-12 |
2018-01-16 |
Medimmune Limited |
Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
|
AU2013328623B8
(en)
|
2012-10-12 |
2017-06-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
ES2680153T3
(es)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
|
NZ707543A
(en)
|
2012-10-12 |
2018-09-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CA2885305C
(en)
|
2012-10-12 |
2019-11-12 |
Spirogen Sarl |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
CN110256469B
(zh)
|
2012-10-12 |
2022-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2014062697A2
(en)
*
|
2012-10-16 |
2014-04-24 |
Endocyte, Inc. |
Drug delivery conjugates containing unnatural amino acids and methods for using
|
CN104755482B
(zh)
|
2012-10-30 |
2017-04-26 |
内尔维阿诺医学科学有限公司 |
官能化的9‑溴‑喜树碱衍生物
|
WO2014068079A1
(en)
|
2012-11-01 |
2014-05-08 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
AU2013340449B2
(en)
|
2012-11-05 |
2017-11-30 |
Pfizer Inc. |
Spliceostatin analogs
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
BR112015011118B1
(pt)
|
2012-11-15 |
2022-12-13 |
Endocyte, Inc |
Conjugado; composição farmacêutica; e uso de um conjugado
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
EP2928503B1
(en)
|
2012-12-10 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Conjugates of auristatin compounds
|
WO2014093394A1
(en)
|
2012-12-10 |
2014-06-19 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
JP6484178B2
(ja)
|
2012-12-12 |
2019-03-13 |
プロメガ コーポレイションPromega Corporation |
生物活性剤の細胞標的の捕捉のための組成物および方法
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
KR20150119848A
(ko)
*
|
2012-12-21 |
2015-10-26 |
바이오얼라이언스 씨.브이. |
친수성 자기-희생 링커 및 그것의 포합체
|
US20150314007A1
(en)
|
2012-12-21 |
2015-11-05 |
Glykos Finland Oy |
Linker-payload molecule conjugates
|
EP2934585B1
(en)
|
2012-12-21 |
2018-06-13 |
Seattle Genetics, Inc. |
Anti-ntb-a antibodies and related compositions and methods
|
EP2943506B1
(en)
|
2013-01-10 |
2024-03-13 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
EP3566750A3
(en)
|
2013-02-28 |
2020-04-08 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
JP6423804B2
(ja)
|
2013-02-28 |
2018-11-14 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤を含む複合体
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10168323B2
(en)
|
2013-03-15 |
2019-01-01 |
Promega Corporation |
Compositions and methods for capture of cellular targets of bioactive agents
|
CN105358174B
(zh)
|
2013-03-15 |
2019-03-15 |
酵活有限公司 |
具细胞毒性和抗有丝***的化合物以及其使用方法
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
KR102305226B1
(ko)
|
2013-03-15 |
2021-09-29 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
항-egfr 항체 약물 접합체 제형
|
WO2014140300A1
(en)
|
2013-03-15 |
2014-09-18 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
RU2015144186A
(ru)
|
2013-03-15 |
2017-04-24 |
Эббви Инк. |
Очистка конъюгата антитело-лекарственное средство (аdс)
|
JP6594855B2
(ja)
|
2013-03-15 |
2019-10-23 |
ゼンコア インコーポレイテッド |
ヘテロ二量体タンパク質
|
US11072812B2
(en)
|
2013-03-15 |
2021-07-27 |
Promega Corporation |
Substrates for covalent tethering of proteins to functional groups or solid surfaces
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
LT2991683T
(lt)
|
2013-05-02 |
2019-12-27 |
Glykos Finland Oy |
Glikoproteino arba glikano konjugatai su toksine medžiaga
|
CA2910029A1
(en)
|
2013-05-31 |
2014-12-04 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
KR20160015286A
(ko)
|
2013-05-31 |
2016-02-12 |
제넨테크, 인크. |
항-세포벽 테이코산 항체 및 접합체
|
GB201309807D0
(en)
|
2013-05-31 |
2013-07-17 |
Pharma Mar Sau |
Antibody drug conjugates
|
RU2015156888A
(ru)
|
2013-06-04 |
2017-07-14 |
Сайтомкс Терапьютикс, Инк. |
Композиции и методы конъюгирования активируемых антител
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
JP6744212B2
(ja)
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
ポリペプチドの酵素的結合
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
WO2015017552A1
(en)
*
|
2013-08-01 |
2015-02-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
GB2516882A
(en)
|
2013-08-02 |
2015-02-11 |
Univ Bradford |
Tumour-targeted theranostic
|
US9542023B2
(en)
|
2013-08-07 |
2017-01-10 |
Synaptics Incorporated |
Capacitive sensing using matrix electrodes driven by routing traces disposed in a source line layer
|
EP3033111B1
(en)
|
2013-08-12 |
2019-03-13 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
SG11201601424PA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Site-specific antibody conjugation methods and compositions
|
KR20160055253A
(ko)
|
2013-09-12 |
2016-05-17 |
할로자임, 아이엔씨 |
변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
|
KR20160055252A
(ko)
|
2013-09-17 |
2016-05-17 |
제넨테크, 인크. |
항-lgr5 항체의 사용 방법
|
US20150091842A1
(en)
|
2013-09-30 |
2015-04-02 |
Synaptics Incorporated |
Matrix sensor for image touch sensing
|
US9298325B2
(en)
|
2013-09-30 |
2016-03-29 |
Synaptics Incorporated |
Processing system for a capacitive sensing device
|
US10042489B2
(en)
|
2013-09-30 |
2018-08-07 |
Synaptics Incorporated |
Matrix sensor for image touch sensing
|
US9459367B2
(en)
|
2013-10-02 |
2016-10-04 |
Synaptics Incorporated |
Capacitive sensor driving technique that enables hybrid sensing or equalization
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
HUE046816T2
(hu)
|
2013-10-11 |
2020-03-30 |
Asana Biosciences Llc |
Fehérje-polimer-gyógyszer konjugátumok
|
US9849191B2
(en)
|
2013-10-11 |
2017-12-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
US10081682B2
(en)
|
2013-10-11 |
2018-09-25 |
Oxford Bio Therapeutics Ltd. |
Conjugated antibodies against LY75 for the treatment of cancer
|
ES2764833T3
(es)
|
2013-10-11 |
2020-06-04 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
Anticuerpos contra TEM8 y su uso
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2015052532A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
CA2934030A1
(en)
|
2013-10-15 |
2015-04-23 |
Sorrento Therapeutics Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
NZ717668A
(en)
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
RS65324B1
(sr)
|
2013-10-18 |
2024-04-30 |
Novartis Ag |
Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
|
US9274662B2
(en)
|
2013-10-18 |
2016-03-01 |
Synaptics Incorporated |
Sensor matrix pad for performing multiple capacitive sensing techniques
|
AU2014340378A1
(en)
|
2013-10-21 |
2016-04-21 |
Genentech, Inc. |
Anti-Ly6E antibodies and methods of use
|
US9495046B2
(en)
|
2013-10-23 |
2016-11-15 |
Synaptics Incorporated |
Parasitic capacitance filter for single-layer capacitive imaging sensors
|
US9081457B2
(en)
|
2013-10-30 |
2015-07-14 |
Synaptics Incorporated |
Single-layer muti-touch capacitive imaging sensor
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
CA2929386C
(en)
|
2013-11-07 |
2023-01-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Neuregulin allosteric anti-her3 antibody
|
MX2016006551A
(es)
|
2013-11-25 |
2016-09-06 |
Seattle Genetics Inc |
Preparacion de anticuerpos de cultivos de celula de ovario de hamster chino para conjugacion.
|
JP6525474B2
(ja)
*
|
2013-12-06 |
2019-06-05 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
オーロラキナーゼ阻害剤と抗cd30抗体の併用
|
AU2014362238A1
(en)
|
2013-12-13 |
2016-06-09 |
Genentech, Inc. |
Anti-CD33 antibodies and immunoconjugates
|
MX2016007578A
(es)
|
2013-12-16 |
2016-10-03 |
Genentech Inc |
Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
|
WO2015095755A1
(en)
|
2013-12-19 |
2015-06-25 |
Seattle Genetics, Inc. |
Methylene carbamate linkers for use with targeted-drug conjugates
|
EP3082878B1
(en)
|
2013-12-19 |
2022-10-05 |
Seagen Inc. |
Methylene carbamate linkers for use with targeted-drug conjugates
|
US10675355B2
(en)
|
2013-12-27 |
2020-06-09 |
Var2 Pharmaceuticals Aps |
VAR2CSA-drug conjugates
|
PL3086815T3
(pl)
|
2013-12-27 |
2022-06-13 |
Zymeworks Inc. |
Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CN114716555A
(zh)
|
2014-01-10 |
2022-07-08 |
博笛生物科技有限公司 |
靶向表达egfr的肿瘤的化合物和组合物
|
EP3094350B1
(en)
|
2014-01-15 |
2020-03-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Cartilage targeting agents and their use
|
CA2935393A1
(en)
|
2014-01-24 |
2015-07-30 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
CA2937561A1
(en)
|
2014-01-29 |
2015-08-06 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
|
FR3017298B1
(fr)
|
2014-02-07 |
2016-03-04 |
Centre Nat Rech Scient |
Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
|
CA3211226A1
(en)
|
2014-02-11 |
2015-08-20 |
Seagen Inc. |
Selective reduction of proteins
|
SG11201605886RA
(en)
*
|
2014-02-17 |
2016-09-29 |
Seattle Genetics Inc |
Hydrophilic antibody-drug conjugates
|
JP2017514143A
(ja)
|
2014-02-21 |
2017-06-01 |
アッヴィ・ステムセントルクス・エル・エル・シー |
メラノーマに使用するための抗dll3抗体および薬物コンジュゲート
|
US9798429B2
(en)
|
2014-02-28 |
2017-10-24 |
Synaptics Incorporated |
Guard electrodes in a sensing stack
|
CN114262344A
(zh)
|
2014-02-28 |
2022-04-01 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
IL295906A
(en)
|
2014-03-21 |
2022-10-01 |
Abbvie Inc |
Antibodies against egfr and drug antibody conjugates
|
EA201691925A1
(ru)
|
2014-03-28 |
2017-06-30 |
Ксенкор, Инк. |
Биспецифические антитела, которые связываются с cd38 и cd3
|
US10133421B2
(en)
|
2014-04-02 |
2018-11-20 |
Synaptics Incorporated |
Display stackups for matrix sensor
|
US9260478B2
(en)
|
2014-04-04 |
2016-02-16 |
Shanghui Hu |
Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
US9927832B2
(en)
|
2014-04-25 |
2018-03-27 |
Synaptics Incorporated |
Input device having a reduced border region
|
US9690397B2
(en)
|
2014-05-20 |
2017-06-27 |
Synaptics Incorporated |
System and method for detecting an active pen with a matrix sensor
|
JP5924795B2
(ja)
|
2014-06-13 |
2016-05-25 |
テンボロン オイ |
複合体
|
WO2015189478A1
(en)
|
2014-06-13 |
2015-12-17 |
Glykos Finland Oy |
Payload-polymer-protein conjugates
|
CN106661124A
(zh)
|
2014-06-20 |
2017-05-10 |
荷商台医(有限合伙)公司 |
抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
|
WO2015197919A1
(en)
|
2014-06-25 |
2015-12-30 |
Glykos Finland Oy |
Antibody drug conjugates binding to high-mannose n-glycan
|
AU2015282627B2
(en)
|
2014-06-30 |
2020-04-02 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
AU2015286569B2
(en)
|
2014-07-11 |
2021-04-15 |
Genmab A/S |
Antibodies binding AXL
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
AU2015292326A1
(en)
|
2014-07-24 |
2017-02-23 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
MX2017001022A
(es)
|
2014-07-24 |
2017-12-20 |
Genentech Inc |
Metodos para conjugar un agente a un resto tiol en una proteina que contiene al menos un enlace trisulfuro.
|
KR102615681B1
(ko)
|
2014-08-28 |
2023-12-18 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于***的抗-pd-l1结合物
|
EP3900742B1
(en)
|
2014-09-11 |
2024-05-15 |
Seagen Inc. |
Targeted delivery of tertiary amine-containing drug substances
|
PE20170670A1
(es)
|
2014-09-12 |
2017-06-06 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
DK3191135T3
(da)
|
2014-09-12 |
2020-10-12 |
Genentech Inc |
Anti-HER2-antistoffer og immunokonjugater
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
AR101844A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos y conjugados modificados genéticamente con cisteína
|
WO2016041082A1
(en)
|
2014-09-17 |
2016-03-24 |
CDRD Ventures, Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
CA3069221C
(en)
|
2014-09-23 |
2023-04-04 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
GB201416960D0
(en)
|
2014-09-25 |
2014-11-12 |
Antikor Biopharma Ltd |
Biological materials and uses thereof
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
CA2966005C
(en)
|
2014-10-31 |
2021-04-27 |
Abbvie Biotherapeutics Inc. |
Anti-cs1 antibodies and antibody drug conjugates
|
ES2735375T3
(es)
|
2014-11-05 |
2019-12-18 |
Nerviano Medical Sciences Srl |
Derivados funcionalizados de morfolinil antraciclina
|
RU2020126237A
(ru)
|
2014-11-19 |
2020-12-01 |
Аксон Ньюросайенс Се |
Гуманизированные тау-антитела при болезни альцгеймера
|
CN104609464B
(zh)
*
|
2014-11-21 |
2017-01-04 |
中国科学院电工研究所 |
一种PbS纳米片的制备方法
|
CA2968447A1
(en)
|
2014-11-25 |
2016-06-02 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
PE20171103A1
(es)
|
2014-11-26 |
2017-08-07 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38
|
KR20170086542A
(ko)
|
2014-12-03 |
2017-07-26 |
제넨테크, 인크. |
항-스타필로코쿠스 아우레우스 항체 리파마이신 콘주게이트 및 그것의 용도
|
MX2017007055A
(es)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Axlに対するヒトモノクローナル抗体
|
BR112017012351A2
(pt)
|
2014-12-09 |
2018-02-27 |
Abbvie Inc |
compostos inibidores de bcl xl que têm permeabilidade celular baixa e conjugados de fármaco-anticorpo que incluem os mesmos
|
BR112017012377A2
(pt)
|
2014-12-09 |
2018-04-24 |
Abbvie Inc |
conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
US10175827B2
(en)
|
2014-12-23 |
2019-01-08 |
Synaptics Incorporated |
Detecting an active pen using a capacitive sensing device
|
US10795471B2
(en)
|
2015-01-05 |
2020-10-06 |
Synaptics Incorporated |
Modulating a reference voltage to perform capacitive sensing
|
US10188759B2
(en)
|
2015-01-07 |
2019-01-29 |
Endocyte, Inc. |
Conjugates for imaging
|
EA201791550A1
(ru)
|
2015-01-14 |
2017-11-30 |
Бристол-Маерс Сквибб Компани |
Димеры бензодиазепинов, их конъюгаты и способы их получения и применения
|
SG11201705645YA
(en)
|
2015-01-14 |
2017-08-30 |
Bristol Myers Squibb Co |
Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
|
GB201501004D0
(en)
|
2015-01-21 |
2015-03-04 |
Cancer Rec Tech Ltd |
Inhibitors
|
CN107849090A
(zh)
*
|
2015-01-28 |
2018-03-27 |
索伦托医疗有限公司 |
抗体药物偶联物
|
WO2016126611A1
(en)
|
2015-02-02 |
2016-08-11 |
The University Of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
WO2016141230A1
(en)
|
2015-03-05 |
2016-09-09 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
ES2884844T3
(es)
|
2015-03-09 |
2021-12-13 |
Agensys Inc |
Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
|
KR20170128256A
(ko)
|
2015-03-18 |
2017-11-22 |
시애틀 지네틱스, 인크. |
Cd48 항체 및 이의 접합체
|
US9939972B2
(en)
|
2015-04-06 |
2018-04-10 |
Synaptics Incorporated |
Matrix sensor with via routing
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
CN106188293A
(zh)
|
2015-04-17 |
2016-12-07 |
江苏恒瑞医药股份有限公司 |
抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
US10591465B2
(en)
|
2015-05-12 |
2020-03-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
|
ES2898023T3
(es)
|
2015-05-22 |
2022-03-03 |
Inst Nat Sante Rech Med |
Fragmentos de anticuerpos monoclonales humanos que inhiben tanto la actividad catalítica de Cath-D como su unión al receptor LRP1
|
WO2016189091A1
(en)
|
2015-05-26 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
CA2989347A1
(en)
|
2015-06-12 |
2016-12-15 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
JP2018518506A
(ja)
|
2015-06-23 |
2018-07-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
大環状ベンゾジアゼピン二量体、その結合体の製造および使用
|
US9720541B2
(en)
|
2015-06-30 |
2017-08-01 |
Synaptics Incorporated |
Arrangement of sensor pads and display driver pads for input device
|
US10095948B2
(en)
|
2015-06-30 |
2018-10-09 |
Synaptics Incorporated |
Modulation scheme for fingerprint sensing
|
IL303690A
(en)
|
2015-06-30 |
2023-08-01 |
Seagen Inc |
Anti–NTB–A antibodies and related preparations and methods
|
US9715304B2
(en)
|
2015-06-30 |
2017-07-25 |
Synaptics Incorporated |
Regular via pattern for sensor-based input device
|
DK3319993T3
(da)
|
2015-07-10 |
2020-04-20 |
Genmab As |
AXL-SPECIFIKKE antistof-lægemiddelkonjugater til kræftbehandling
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
CA2992509A1
(en)
|
2015-07-22 |
2017-01-26 |
Inatherys |
Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
|
CN205028263U
(zh)
|
2015-09-07 |
2016-02-10 |
辛纳普蒂克斯公司 |
一种电容传感器
|
US10037112B2
(en)
|
2015-09-30 |
2018-07-31 |
Synaptics Incorporated |
Sensing an active device'S transmission using timing interleaved with display updates
|
US10722593B2
(en)
|
2015-10-02 |
2020-07-28 |
Sirenas Llc |
Anti-cancer compounds and conjugates thereof
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
CN108779162B
(zh)
|
2015-10-09 |
2021-12-07 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
EP3362088B1
(en)
|
2015-10-12 |
2020-11-25 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
CN107043406B
(zh)
*
|
2015-11-03 |
2021-08-17 |
财团法人工业技术研究院 |
化合物、连接子-药物、及配体-药物耦合体
|
CN108289952B
(zh)
|
2015-11-19 |
2021-02-05 |
雷维托普有限公司 |
用于对非所要细胞进行重定向杀灭的两组分***的功能性抗体片段互补作用
|
EP3383910A1
(en)
|
2015-11-30 |
2018-10-10 |
AbbVie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
JP2019500327A
(ja)
|
2015-11-30 |
2019-01-10 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
WO2017096311A1
(en)
|
2015-12-04 |
2017-06-08 |
Seattle Genetics, Inc. |
Conjugates of quaternized tubulysin compounds
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
US10067587B2
(en)
|
2015-12-29 |
2018-09-04 |
Synaptics Incorporated |
Routing conductors in an integrated display device and sensing device
|
CN106933400B
(zh)
|
2015-12-31 |
2021-10-29 |
辛纳普蒂克斯公司 |
单层传感器图案和感测方法
|
KR20180117102A
(ko)
|
2016-01-08 |
2018-10-26 |
바이오얼라이언스 씨.브이. |
사가 항-psgl-1 항체 및 이들의 용도
|
BR112018014277A2
(pt)
|
2016-01-13 |
2018-12-18 |
Genmab As |
formulação, e, método de preparação de uma solução injetável de um axl-adc
|
CN108848669B
(zh)
|
2016-01-20 |
2022-06-07 |
斯克利普斯研究所 |
Ror1抗体组合物和相关方法
|
AU2017211120C1
(en)
*
|
2016-01-25 |
2021-10-07 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
MX2018009085A
(es)
|
2016-01-27 |
2019-05-09 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
|
PT3411076T
(pt)
|
2016-02-05 |
2021-06-17 |
Rigshospitalet |
Conjugados anticorpo-fármaco que têm como alvo uparap
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
MX2018009700A
(es)
|
2016-02-17 |
2019-01-24 |
Seattle Genetics Inc |
Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
|
US11191821B2
(en)
|
2016-02-27 |
2021-12-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccine formulations and use thereof for inducing an immune response
|
WO2017151425A1
(en)
|
2016-02-29 |
2017-09-08 |
Madrigal Pharmaceuticals, Inc. |
Hsp90 inhibitor drug conjugates
|
TW202408592A
(zh)
*
|
2016-03-02 |
2024-03-01 |
日商衛材R&D企管股份有限公司 |
基於艾日布林之抗體-藥物結合物及使用方法
|
MX2018010491A
(es)
|
2016-03-04 |
2018-11-09 |
Genentech Inc |
Proceso para la preparacion de un conjugado anticuerpo-rifamicina.
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
KR102438140B1
(ko)
|
2016-03-22 |
2022-08-31 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
인간화 항-클라우딘-1 항체 및 이의 용도
|
US10913780B2
(en)
|
2016-03-24 |
2021-02-09 |
The Administrators Of The Tulane Educational Fund |
Conjugates, their compositions, their uses, and their methods of making
|
JP7073266B2
(ja)
|
2016-03-25 |
2022-05-23 |
シージェン インコーポレイテッド |
Peg化薬物リンカー及びその中間体を調製するためのプロセス
|
ES2948846T3
(es)
|
2016-03-29 |
2023-09-20 |
Toray Industries |
Derivado peptídico y uso del mismo
|
KR20180135458A
(ko)
|
2016-04-26 |
2018-12-20 |
알.피.쉐러 테크놀러지즈 엘엘씨 |
항체 컨쥬게이트 및 이의 제조 및 이용 방법
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
US11254742B2
(en)
|
2016-05-13 |
2022-02-22 |
Bioatla, Inc. |
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
SG10201914095SA
(en)
|
2016-05-17 |
2020-03-30 |
Abbvie Biotherapeutics Inc |
ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック, インコーポレイテッド |
部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
|
US10668166B2
(en)
|
2016-05-30 |
2020-06-02 |
Toxinvent Ou |
Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
|
JP7043425B2
(ja)
|
2016-06-06 |
2022-03-29 |
ジェネンテック, インコーポレイテッド |
シルベストロール抗体-薬物コンジュゲート及び使用方法
|
IL308054A
(en)
|
2016-06-08 |
2023-12-01 |
Abbvie Inc |
Drug conjugates of anti-EGFR antibodies
|
EP3468598A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
EP3468615A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-egfr antibody drug conjugates
|
WO2017214462A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
JP2019526529A
(ja)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
抗b7−h3抗体及び抗体薬物コンジュゲート
|
TWI762487B
(zh)
|
2016-06-08 |
2022-05-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
EP3469000A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
EP3468616A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-egfr antibody drug conjugates
|
WO2017214458A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
JP7021127B2
(ja)
|
2016-06-28 |
2022-02-16 |
ゼンコア インコーポレイテッド |
ソマトスタチン受容体2に結合するヘテロ二量体抗体
|
MA45945A
(fr)
|
2016-08-09 |
2019-06-19 |
Seattle Genetics Inc |
Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées
|
CN106674347B
(zh)
*
|
2016-08-16 |
2019-12-13 |
滨州医学院 |
一种新型耳抑素抗体
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
AU2017321894A1
(en)
|
2016-09-02 |
2019-03-14 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duoCARs
|
US10517958B2
(en)
|
2016-10-04 |
2019-12-31 |
Zymeworks Inc. |
Compositions and methods for the treatment of platinum-drug resistant cancer
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
MA46660A
(fr)
|
2016-10-18 |
2019-08-28 |
Seattle Genetics Inc |
Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide
|
CA3041254A1
(en)
|
2016-10-19 |
2018-04-26 |
Invenra Inc. |
Antibody constructs
|
JP2019535306A
(ja)
|
2016-10-25 |
2019-12-12 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル) |
Cd160膜貫通型アイソフォームと結合するモノクローナル抗体
|
CA3041979A1
(en)
|
2016-10-28 |
2018-05-03 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
MA46700A
(fr)
|
2016-11-01 |
2021-05-19 |
Genmab Bv |
Variants polypeptidiques et ses utilisations
|
WO2018089373A2
(en)
|
2016-11-08 |
2018-05-17 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
MA46759A
(fr)
|
2016-11-14 |
2019-09-18 |
Millennium Pharm Inc |
Dosage de conjugués anticorps-médicament anti-cd30 pour humain non adulte
|
KR20220150408A
(ko)
|
2016-11-14 |
2022-11-10 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
US10864279B2
(en)
|
2016-12-16 |
2020-12-15 |
Industrial Technology Research Institute |
Linker-drug and antibody-drug conjugate (ADC) employing the same
|
KR102312222B1
(ko)
|
2016-12-22 |
2021-10-12 |
우니베르시따 델리 스투디 만냐 그레챠 카탄차로 |
Cd43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체
|
KR102015524B1
(ko)
*
|
2016-12-26 |
2019-08-29 |
인터올리고 주식회사 |
압타머-약물 콘쥬게이트 및 그 용도
|
CN106854245A
(zh)
*
|
2016-12-28 |
2017-06-16 |
无锡傲锐东源生物科技有限公司 |
抗cd30蛋白单克隆抗体及其用途
|
ES2936803T3
(es)
|
2017-01-09 |
2023-03-22 |
Lentigen Tech Inc |
Composiciones y métodos para tratar el cáncer con inmunoterapia antimesotelina
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
AU2018217926B2
(en)
|
2017-02-08 |
2019-10-03 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
CN110461871B
(zh)
|
2017-02-16 |
2024-04-26 |
索纳特生物疗法公司 |
白蛋白结合结构域融合蛋白
|
US20210330801A1
(en)
|
2017-03-02 |
2021-10-28 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
CA3057838A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
IL269398B2
(en)
|
2017-03-24 |
2024-05-01 |
Seagen Inc |
A process for the preparation of glucuronide-drug binders and their intermediates
|
JP7247101B2
(ja)
|
2017-04-03 |
2023-03-28 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Steap-1に結合する抗体
|
CA3056261A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
JP2020517609A
(ja)
|
2017-04-18 |
2020-06-18 |
メディミューン リミテッド |
ピロロベンゾジアゼピン複合体
|
US11932694B2
(en)
|
2017-04-19 |
2024-03-19 |
Bluefin Biomedicine, Inc. |
Anti-VTCN1 antibodies and antibody drug conjugates
|
EP3612234B1
(en)
|
2017-04-20 |
2024-03-13 |
ADC Therapeutics SA |
Combination therapy with an anti-axl antibody-drug conjugate
|
MA51189A
(fr)
|
2017-04-27 |
2020-03-04 |
Seattle Genetics Inc |
Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé
|
JOP20190254A1
(ar)
|
2017-04-27 |
2019-10-27 |
Pharma Mar Sa |
مركبات مضادة للأورام
|
AU2018259856A1
(en)
|
2017-04-28 |
2019-11-14 |
Ajinomoto Co., Inc. |
Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
EP3624854A1
(en)
|
2017-05-16 |
2020-03-25 |
Université de Strasbourg |
Protein-drug conjugates and their use in the treatment of cancers
|
MX2019013690A
(es)
|
2017-05-18 |
2020-01-27 |
Regeneron Pharma |
Conjugados de farmaco-proteina con ciclodextrina.
|
KR102344616B1
(ko)
|
2017-05-30 |
2021-12-31 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 |
항-더블코르틴-유사 키나제 1 항체 및 사용 방법
|
US11318211B2
(en)
|
2017-06-14 |
2022-05-03 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
CA3095067A1
(en)
*
|
2017-06-19 |
2018-12-27 |
Sichuan Baili Pharm Co. Ltd |
An antibody-drug conjugate having an acidic self-stabilization junction
|
EP3641802A1
(en)
|
2017-06-22 |
2020-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
US10772971B2
(en)
|
2017-06-22 |
2020-09-15 |
Mersana Therpeutics, Inc. |
Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
|
WO2018237335A1
(en)
|
2017-06-23 |
2018-12-27 |
VelosBio Inc. |
IMMUNOCONJUGUATED ROR1 ANTIBODIES
|
WO2019005756A1
(en)
|
2017-06-28 |
2019-01-03 |
The Rockefeller University |
CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
EP3661964A1
(en)
|
2017-07-31 |
2020-06-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
SI3668874T1
(sl)
|
2017-08-18 |
2022-04-29 |
Medimmune Limited |
Pirolobenzodiazepinski konjugati
|
US10501539B2
(en)
|
2017-09-15 |
2019-12-10 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
US10596270B2
(en)
|
2017-09-18 |
2020-03-24 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
|
BR112020006892A2
(pt)
|
2017-10-11 |
2020-10-06 |
Seattle Genetics, Inc. |
métodos de reduzir efeitos colaterais de terapia de conjugado anticorpo anti-cd30 fármaco
|
JP7356727B2
(ja)
|
2017-10-12 |
2023-10-05 |
慶應義塾 |
アクアポリン3(aqp3)の細胞外ドメインに特異的に結合する抗aqp3モノクローナル抗体、及びその使用
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
EP4279584A3
(en)
|
2017-10-16 |
2024-03-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd22 immunotherapy
|
CN107759699A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd30抗原的转基因t细胞及其制备方法与应用
|
JP2021501800A
(ja)
|
2017-11-01 |
2021-01-21 |
シアトル ジェネティクス,インコーポレイティド |
抗cd30抗体薬物複合体療法の副作用を軽減する方法
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
EP3713588A4
(en)
*
|
2017-11-22 |
2021-08-04 |
Seagen Inc. |
ACID MEDIATION ASSAY FOR THE ANALYSIS OF LIGAND-DRUG CONJUGATES
|
CN111727075B
(zh)
|
2017-11-27 |
2024-04-05 |
普渡制药公司 |
靶向人组织因子的人源化抗体
|
JP2021504414A
(ja)
*
|
2017-11-29 |
2021-02-15 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
Cd2+細胞の枯渇のための組成物および方法
|
TWI831759B
(zh)
|
2017-12-01 |
2024-02-11 |
美商思進公司 |
Cd47抗體及其用於治療癌症之用途
|
CA3084495A1
(en)
|
2017-12-01 |
2019-06-06 |
Seattle Genetics, Inc. |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
JP2021506291A
(ja)
|
2017-12-19 |
2021-02-22 |
ゼンコア インコーポレイテッド |
改変されたil−2 fc融合タンパク質
|
CA3086612A1
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
CN111989339A
(zh)
*
|
2018-02-20 |
2020-11-24 |
西雅图基因公司 |
疏水性奥瑞他汀f化合物及其缀合物
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
KR20200138750A
(ko)
|
2018-03-07 |
2020-12-10 |
포슝스베르분드 베를린 에.베. |
알켄 또는 알킨-포스포노티올레이트 및 -포스포네이트로의 화학선택적 티올-접합
|
PL3765525T3
(pl)
|
2018-03-13 |
2023-12-27 |
Zymeworks Bc Inc. |
Koniugaty biparatopowe przeciwciało anty-her2 – lek i sposoby stosowania
|
BR112020018948A2
(pt)
|
2018-03-23 |
2021-01-05 |
Seattle Genetics, Inc. |
Uso de conjugados de fármaco e anticorpo que compreendem agentes de interrupção de tubulina para tratar tumor sólido
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
WO2019212356A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B .V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
WO2019213386A1
(en)
*
|
2018-05-04 |
2019-11-07 |
New Mexico Tech University Research Park Corporation |
Proteasome inhibitors
|
DK3788032T3
(da)
|
2018-05-04 |
2024-04-15 |
Tagworks Pharmaceuticals B V |
Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
|
MX2020011176A
(es)
|
2018-05-07 |
2020-11-12 |
Genmab As |
Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento.
|
KR20210044183A
(ko)
|
2018-05-07 |
2021-04-22 |
젠맵 에이/에스 |
항-pd-1 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
|
SG11202010909RA
(en)
|
2018-05-09 |
2020-12-30 |
Regeneron Pharma |
Anti-msr1 antibodies and methods of use thereof
|
CU20200089A7
(es)
|
2018-06-01 |
2021-07-02 |
Novartis Ag |
Moléculas de unión contra bcma
|
EP3802580A1
(en)
|
2018-06-05 |
2021-04-14 |
King's College London |
Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
AU2019285353A1
(en)
|
2018-06-14 |
2021-01-07 |
Ajinomoto Co., Inc. |
Compound comprising substance having affinity for antibody, cleavage site and reactive group, or salt thereof
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
EP3811978A4
(en)
|
2018-06-14 |
2022-03-16 |
Ajinomoto Co., Inc. |
SUBSTANCE HAVING AFFINITY FOR AN ANTIBODY, AND COMPOUND OR SALT THEREOF HAVING A BIOORTHOGONAL FUNCTIONAL GROUP
|
US11530274B2
(en)
|
2018-07-02 |
2022-12-20 |
Amgen Inc. |
Anti-STEAP1 antigen-binding protein
|
JP2021533102A
(ja)
|
2018-07-27 |
2021-12-02 |
プロメガ コーポレイションPromega Corporation |
キノン含有複合体
|
KR20210057124A
(ko)
|
2018-09-11 |
2021-05-20 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 용도
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
JP2022511337A
(ja)
|
2018-09-19 |
2022-01-31 |
インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
WO2020061498A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
KR20210066833A
(ko)
|
2018-09-26 |
2021-06-07 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
엑사테칸 유사체의 리간드-약물 접합체, 이를 위한 제조 방법, 및 이의 적용
|
AU2019350865A1
(en)
|
2018-09-26 |
2021-04-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
|
CA3114922A1
(en)
|
2018-10-01 |
2020-04-09 |
Seagen Inc. |
Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
TWI824043B
(zh)
|
2018-10-25 |
2023-12-01 |
西班牙商瑪製藥股份有限公司 |
藥物抗體共軛物
|
EA202191175A1
(ru)
|
2018-10-29 |
2021-09-08 |
Мерсана Терапьютикс, Инк. |
Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
|
WO2020092210A1
(en)
|
2018-10-30 |
2020-05-07 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
|
JPWO2020090979A1
(ja)
|
2018-10-31 |
2021-09-24 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
EP3647419A1
(en)
|
2018-11-02 |
2020-05-06 |
NBE Therapeutics AG |
Sortase f and its use in methods for conjugation
|
JP2022512860A
(ja)
|
2018-11-06 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
|
AU2019385497A1
(en)
|
2018-11-20 |
2021-06-17 |
Cornell University |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
JP2022513682A
(ja)
|
2018-11-30 |
2022-02-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd38免疫療法によりがんを処置するための組成物および方法
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
CN113227119A
(zh)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
|
WO2020120786A1
(en)
|
2018-12-14 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
EP3898699A1
(en)
|
2018-12-19 |
2021-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
GB201820864D0
(en)
*
|
2018-12-20 |
2019-02-06 |
J A Kemp |
Antibody-drug conjugates
|
WO2020127968A1
(en)
|
2018-12-20 |
2020-06-25 |
Marino Stephen F |
Protein-drug conjugate comprising a monomeric form of proteinase 3
|
KR20240015162A
(ko)
|
2018-12-21 |
2024-02-02 |
어비디티 바이오사이언시스 인크. |
항트랜스페린 수용체 항체 및 이의 용도
|
CA3127113A1
(en)
|
2019-01-30 |
2020-08-06 |
Dongxu Sun |
Anti-gal3 antibodies and uses thereof
|
AU2020219732A1
(en)
|
2019-02-05 |
2021-08-05 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
TWI756633B
(zh)
|
2019-02-15 |
2022-03-01 |
大陸商上海藥明生物技術有限公司 |
具有改善的同質性的抗體-藥物綴合物、其藥物組合物、用途和製備方法
|
CN109652384B
(zh)
*
|
2019-02-21 |
2021-10-26 |
昆明理工大学 |
一种体外培养戊型肝炎病毒的方法
|
JP2022522344A
(ja)
|
2019-02-26 |
2022-04-18 |
インスピアーナ, インコーポレイテッド |
高親和性抗mertk抗体およびその使用
|
CN114173875A
(zh)
|
2019-03-01 |
2022-03-11 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
EP3934668A1
(en)
|
2019-03-06 |
2022-01-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
SG11202109066RA
(en)
|
2019-03-19 |
2021-09-29 |
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
WO2020191342A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
WO2020191344A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
WO2020213084A1
(en)
|
2019-04-17 |
2020-10-22 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
AU2020268749A1
(en)
|
2019-05-06 |
2021-12-02 |
Centre National De La Recherche Scientifique |
New therapeutic vectors and prodrugs for treating cancers
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
JOP20210309A1
(ar)
|
2019-05-21 |
2023-01-30 |
Novartis Ag |
جزيئات ربط بـ cd19 واستخدامتها
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
CN118345101A
(zh)
|
2019-05-30 |
2024-07-16 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
US20220233709A1
(en)
|
2019-06-05 |
2022-07-28 |
Seagen Inc. |
Masked Antibody Formulations
|
WO2020247574A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Methods of purifying masked antibodies
|
CN115135628A
(zh)
|
2019-06-17 |
2022-09-30 |
泰克沃尔科斯制药有限公司 |
快速高效点击释放的化合物
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
WO2021003297A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
US20210030885A1
(en)
|
2019-07-22 |
2021-02-04 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
KR20220041915A
(ko)
|
2019-08-06 |
2022-04-01 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
바이오제약 조성물 및 관련 방법
|
US20210040197A1
(en)
|
2019-08-08 |
2021-02-11 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
WO2021030251A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
US20230218774A1
(en)
|
2019-09-05 |
2023-07-13 |
Pharma Mar, S.A. |
Drug antibody conjugates
|
CN112125915A
(zh)
|
2019-09-18 |
2020-12-25 |
四川百利药业有限责任公司 |
一种喜树碱衍生物及其偶联物
|
AR120079A1
(es)
|
2019-09-19 |
2022-02-02 |
Seattle Genetics Inc |
Liberación selectiva de fármacos de conjugados internalizados de compuestos biológicamente activos
|
US20220347313A1
(en)
|
2019-09-25 |
2022-11-03 |
Seagen, Inc. |
Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers
|
WO2021060439A1
(ja)
|
2019-09-26 |
2021-04-01 |
日油株式会社 |
ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール
|
WO2021066869A1
(en)
|
2019-10-04 |
2021-04-08 |
TAE Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
CA3155634A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
JP2022553640A
(ja)
|
2019-10-10 |
2022-12-26 |
コディアック サイエンシーズ インコーポレイテッド |
眼障害を処置する方法
|
CA3153880A1
(en)
|
2019-10-18 |
2020-06-09 |
Juana Elva HERNANDEZ MONTALVO |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
US20240123081A1
(en)
|
2019-10-25 |
2024-04-18 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
JP2022553830A
(ja)
|
2019-11-05 |
2022-12-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
N末端scFv多重特異性結合分子
|
EP4055051A1
(en)
|
2019-11-07 |
2022-09-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
JP2023550743A
(ja)
|
2019-11-22 |
2023-12-05 |
メドイミューン・リミテッド |
E2ユビキチン又はユビキチン様コンジュゲートドメインを含む融合タンパク質並びに特定のタンパク質分解のためのドメインの標的化
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
US20230090552A1
(en)
|
2020-01-08 |
2023-03-23 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
CA3168654A1
(en)
|
2020-01-22 |
2021-07-29 |
Shanghai Senhui Medicine Co., Ltd. |
Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
US20230126689A1
(en)
|
2020-03-06 |
2023-04-27 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
CN115243726A
(zh)
|
2020-03-11 |
2022-10-25 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其使用方法
|
US11555190B2
(en)
|
2020-03-19 |
2023-01-17 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
CN115103691A
(zh)
|
2020-03-25 |
2022-09-23 |
江苏恒瑞医药股份有限公司 |
一种含抗体药物偶联物的药物组合物及其用途
|
JP2023521956A
(ja)
|
2020-03-25 |
2023-05-26 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗体薬物複合体の調製方法
|
KR20220161378A
(ko)
|
2020-03-27 |
2022-12-06 |
어비디티 바이오사이언시스 인크. |
근이영양증의 치료용 조성물 및 방법
|
EP4126241A1
(en)
|
2020-03-27 |
2023-02-08 |
Novartis AG |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
BR112022020332A2
(pt)
|
2020-04-10 |
2022-12-13 |
Seagen Inc |
Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
|
MX2022013298A
(es)
|
2020-04-21 |
2022-11-30 |
Pharma Mar Sa |
Conjugados de anticuerpos de farmacos.
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
WO2021221927A1
(en)
|
2020-04-27 |
2021-11-04 |
Parsons Corporation |
Narrowband iq signal obfuscation
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
AU2021275489A1
(en)
|
2020-05-20 |
2022-12-01 |
Centre National De La Recherche Scientifique - Cnrs - |
Single domain antibodies and their use in cancer therapies
|
TW202210084A
(zh)
|
2020-06-05 |
2022-03-16 |
新加坡商泰莎治療有限公司 |
Cd30陽性癌症之治療
|
JPWO2021251358A1
(el)
|
2020-06-09 |
2021-12-16 |
|
|
CN116829581A
(zh)
|
2020-06-22 |
2023-09-29 |
莱蒂恩技术公司 |
用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
|
EP4171652A1
(en)
|
2020-06-29 |
2023-05-03 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
CA3189225A1
(en)
|
2020-08-04 |
2022-02-10 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
CN112062855A
(zh)
|
2020-08-26 |
2020-12-11 |
康诺亚生物医药科技(成都)有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
JP2023542141A
(ja)
|
2020-09-15 |
2023-10-05 |
ザ ユニバーシティー オブ モンタナ |
繊維状バクテリオファージを標的化する組成物および方法
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
MX2023003404A
(es)
|
2020-09-28 |
2023-03-31 |
Seagen Inc |
Anticuerpos anti-l1vi humanizados para el tratamiento del cancer.
|
EP4229090A1
(en)
|
2020-10-16 |
2023-08-23 |
Université d'Aix-Marseille |
Anti-gpc4 single domain antibodies
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
MX2023004941A
(es)
|
2020-11-08 |
2023-07-12 |
Seagen Inc |
Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
|
CN116490614A
(zh)
|
2020-11-23 |
2023-07-25 |
康诺亚生物医药科技(成都)有限公司 |
一种双特异性抗体及其用途
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技(成都)有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技(成都)有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
EP4261225A1
(en)
|
2020-12-10 |
2023-10-18 |
Eutilex Co., Ltd. |
Anti-pd-1 antibody and uses thereof
|
CA3201178A1
(en)
|
2020-12-23 |
2022-06-30 |
Heinrich Leonhardt |
Improved cd30 targeting antibody drug conjugates and uses thereof
|
CN114685657A
(zh)
|
2020-12-31 |
2022-07-01 |
康诺亚生物医药科技(成都)有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
CN114716548A
(zh)
|
2021-01-05 |
2022-07-08 |
(株)爱恩德生物 |
抗-fgfr3抗体及其用途
|
JP2024505428A
(ja)
|
2021-01-14 |
2024-02-06 |
アンスティテュ キュリー |
Her2単一ドメイン抗体バリアントおよびそのcar
|
CA3208290A1
(en)
|
2021-01-18 |
2022-07-21 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained by using the same
|
JPWO2022154116A1
(el)
|
2021-01-18 |
2022-07-21 |
|
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
EP4297794A2
(en)
|
2021-02-26 |
2024-01-03 |
Forschungsverbund Berlin E.V. |
Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives
|
EP4301782A1
(en)
|
2021-03-05 |
2024-01-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
CN116964076A
(zh)
|
2021-03-11 |
2023-10-27 |
味之素株式会社 |
化合物或其盐、以及由它们得到的抗体
|
WO2022196675A1
(ja)
|
2021-03-16 |
2022-09-22 |
味の素株式会社 |
複合体またはその塩、およびその製造方法
|
BR112023018676A2
(pt)
|
2021-03-18 |
2023-10-10 |
Seagen Inc |
Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
|
EP4308171A1
(en)
|
2021-03-18 |
2024-01-24 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
WO2022200303A1
(en)
|
2021-03-23 |
2022-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of t cell-lymphomas
|
US20240191272A1
(en)
|
2021-03-31 |
2024-06-13 |
Microbiopharm Japan Co., Ltd. |
Method for producing antibody-drug conjugate and enzyme used for the same
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
WO2022226130A1
(en)
|
2021-04-21 |
2022-10-27 |
Indapta Therapeutics, Inc. |
Methods of treatment and dosing of natural killer cell compositions
|
JP2024516631A
(ja)
|
2021-04-23 |
2024-04-16 |
プロファウンドバイオ ユーエス カンパニー |
抗cd70抗体、そのコンジュゲートおよびこれを使用する方法
|
CN117545511A
(zh)
|
2021-04-23 |
2024-02-09 |
柏林合作研究学会 |
与不饱和磷(v)化合物的硫醇偶联
|
EP4330379A2
(en)
|
2021-04-27 |
2024-03-06 |
Baylor College of Medicine |
Virus-specific immune cells expressing chimeric antigen receptors
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
|
WO2022248835A1
(en)
|
2021-05-26 |
2022-12-01 |
Oxford Biotherapeutics Ltd |
Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023288252A1
(en)
|
2021-07-13 |
2023-01-19 |
Truebinding, Inc. |
Methods of preventing protein aggregation
|
EP4370211A1
(en)
|
2021-07-14 |
2024-05-22 |
Seagen Inc. |
Antibody masking domains
|
CN117794954A
(zh)
|
2021-08-03 |
2024-03-29 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和稳定同位素标记肽图谱方法
|
EP4380604A1
(en)
|
2021-08-05 |
2024-06-12 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
TW202337499A
(zh)
|
2021-08-07 |
2023-10-01 |
美商建南德克公司 |
使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法
|
KR20240101546A
(ko)
|
2021-09-03 |
2024-07-02 |
고 테라퓨틱스, 인크. |
항-글리코-lamp1 항체 및 그의 용도
|
JPWO2023033129A1
(el)
|
2021-09-03 |
2023-03-09 |
|
|
EP4395810A1
(en)
|
2021-09-03 |
2024-07-10 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
WO2023031445A2
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
FR3126982B1
(fr)
|
2021-09-14 |
2023-09-15 |
Centre Nat Rech Scient |
Vecteurs ciblant la beta-d-n-acetylglucosaminidase
|
IL311452A
(en)
|
2021-09-16 |
2024-05-01 |
Avidity Biosciences Inc |
Compositions and methods for the treatment of FSHD muscular dystrophy
|
CN118369344A
(zh)
|
2021-09-16 |
2024-07-19 |
阿博莱斯制药公司 |
抗人cd45rc结合结构域及其用途
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
AU2022353331A1
(en)
|
2021-09-30 |
2024-04-11 |
Ajinomoto Co., Inc. |
Regioselective conjugate of functional substance and antibody or salt of said conjugate, and antibody derivative and compound for use in production of said conjugate, or salt of said antibody derivative and compound
|
CA3234692A1
(en)
|
2021-09-30 |
2023-04-06 |
Ajinomoto Co., Inc. |
Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof
|
CN115975030B
(zh)
|
2021-09-30 |
2023-09-26 |
杭州邦顺制药有限公司 |
抗cd39抗体-药物偶联物及其用途
|
WO2023072953A1
(en)
|
2021-10-26 |
2023-05-04 |
Tessa Therapeutics Ltd. |
Cell lines for producing a retroviral vector encoding a car
|
AU2022385379A1
(en)
|
2021-11-09 |
2024-06-20 |
Forschungsverbund Berlin E.V. |
Conjugates comprising a phosphorus (v) and a drug moiety
|
KR20240100415A
(ko)
|
2021-11-09 |
2024-07-01 |
투불리스 게엠베하 |
인(v) 및 캄프토테신 모이어티를 포함하는 접합체
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
AU2022395626A1
(en)
|
2021-11-25 |
2024-05-30 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
AU2022404647A1
(en)
|
2021-12-08 |
2024-06-13 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
WO2023104910A1
(en)
|
2021-12-08 |
2023-06-15 |
Tessa Therapeutics Ltd. |
Treatment of lymphoma
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
DK4314031T3
(da)
|
2022-02-15 |
2024-06-17 |
Tagworks Pharmaceuticals B V |
Maskeret il12-protein
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
TW202346576A
(zh)
|
2022-04-13 |
2023-12-01 |
新加坡商泰莎治療有限公司 |
治療性t細胞產品
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
WO2024001669A1
(zh)
|
2022-06-27 |
2024-01-04 |
昱言科技(北京)有限公司 |
靶向itga2的抗体和包含此抗体的抗体药物缀合物
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024041544A1
(en)
*
|
2022-08-22 |
2024-02-29 |
Suzhou Bioreinno Biotechnology Limited Company |
A method of preparing an antibody with site-specific modifications
|
WO2024041543A1
(en)
*
|
2022-08-22 |
2024-02-29 |
Suzhou Bioreinno Biotechnology Limited Company |
A method of preparing an antibody with thiol group site-specific modifications and use of tcep
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
US20240116945A1
(en)
|
2022-09-02 |
2024-04-11 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
WO2024083953A1
(en)
|
2022-10-18 |
2024-04-25 |
Tubulis Gmbh |
Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
|
US20240190958A1
(en)
|
2022-10-18 |
2024-06-13 |
Tubulis Gmbh |
Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
|
WO2024089013A1
(en)
|
2022-10-25 |
2024-05-02 |
Peptomyc, S.L. |
Combination therapy for the treatment of cancer
|
WO2024091437A1
(en)
|
2022-10-25 |
2024-05-02 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
WO2024129628A1
(en)
|
2022-12-14 |
2024-06-20 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|
GB202219154D0
(en)
|
2022-12-19 |
2023-02-01 |
Metacurum Biotech Ab |
Antibodies and uses thereof
|
WO2024133845A1
(en)
|
2022-12-22 |
2024-06-27 |
Tubulis Gmbh |
Conjugates comprising a phosphorus(v) moiety and a drug
|
WO2024152014A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
CN116239513B
(zh)
*
|
2023-05-05 |
2023-08-18 |
天津凯莱英制药有限公司 |
Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物
|